

**WHAT IS CLAIMED IS:**

1. An isolated IL-16 antagonist peptide consisting of CLLS.
2. An isolated IL-16 antagonist peptide of any one of WQCLLS, WQALLS, VVQVVA or VKQVVA.
3. An isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:13).
4. An isolated peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12)
5. An isolated peptide consisting of any one of TGLWQCLLSEGD (SEQ ID NO:14) or VSEEQKVQVVA (SEQ ID NO:15).
6. An IL-16 antagonist peptide comprising Xaa<sub>1</sub>-LL-Xaa<sub>2</sub> wherein Xaa<sub>1</sub> and Xaa<sub>2</sub> is any amino acid (SEQ ID NO:1).
7. The IL-16 antagonist peptide of Claim 6 wherein Xaa<sub>1</sub>-LL-Xaa<sub>2</sub> is identical to the corresponding native sequence of a mammalian IL-16.
8. An IL-16 antagonist peptide comprising CLLS (SEQ ID NO:2).
9. An IL-16 antagonist peptide comprising Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-L-L-Xaa<sub>4</sub> wherein Xaa<sub>1</sub>-Xaa<sub>4</sub> is any amino acid (SEQ ID NO:3).
10. The IL-16 antagonist peptide of Claim 9, wherein Xaa<sub>1</sub> is Trp; Xaa<sub>2</sub> is selected from Gln or Ala, Xaa<sub>3</sub> is selected from Cys or Ala and Xaa<sub>4</sub> is Ser.
11. The IL-16 antagonist peptide of Claim 9, wherein Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-L-L-Xaa<sub>4</sub> identical to the corresponding native sequence of a mammalian IL-16.
12. An IL-16 antagonist peptide comprising WQCLLS (SEQ ID NO:4) or WQALLS (SEQ ID NO:5).



